|Bid||0.800 x 1300|
|Ask||0.900 x 1300|
|Day's Range||0.8500 - 0.8989|
|52 Week Range||0.6000 - 3.5900|
|Beta (3Y Monthly)||3.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.50|
Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today provided an update on its product portfolio for investors that includes anticipated 2019 clinical milestones. “2018 was a year of substantial execution as we assembled a broad and differentiated pipeline of product candidates across women’s health,” stated Sabrina Martucci Johnson, President and Chief Executive Officer of Daré.
The big shareholder groups in Daré Bioscience, Inc. (NASDAQ:DARE) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
Dare Bioscience (DARE) is showing no signs of slowing down as it relates to expanding their women’s health focused pipeline and their potential eventual related commercialization opportunities. Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC. DARE is also required to pay potential future milestones based on “clinical, regulatory, commercial launch and sales events”, and is also subject to paying royalties on any eventual sales. Bacterial Vaginosis, What It Is, How Prevalent and How Is it Treated?
CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...
Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC under which Daré acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans.
By Brian Marckx, CFA NASDAQ:DARE READ THE FULL DARE RESEARCH REPORT Q3 / Pipeline Update Daré (NASDAQ:DARE) reported financial results for their third quarter and provided an operational update. Relative ...
Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the initiation of a content validity study intended to support the use of specific patient reported outcome (PRO) measures to assess efficacy in female sexual arousal disorder (FSAD) patients in the Phase 2b and Phase 3 program for Sildenafil Cream, 3.6%.
Daré Bioscience, Inc. (DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling patients in an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% in normal healthy women. Sildenafil, the active ingredient in Sildenafil Cream, 3.6%, is marketed in an oral dosage form under the brand name Viagra® for the treatment of erectile dysfunction in men.
SAN DIEGO, Nov. 13, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live webcast at 8:30 a.m. Eastern Time on Tuesday, November 13, 2018, to provide a corporate update and to discuss the Company's financial results for the quarter ended September 30, 2018. To access the conference call via phone, dial (844) 831-3031 (domestic) or (443) 637-1284 (International). The conference ID number for the call is 5463588.
SAN DIEGO, Oct. 23, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer,.
Daré (DARE) continues to not only move their various development programs forward, but also continues to add promising candidates to their high-potential women’s health-focused pipeline. Relative to the latter, DARE’s most recent pipeline addition, CatSper, a potential first-in-kind contraceptive for both men and women, was announced in mid-July.
NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Daré Bioscience (DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive health. Daré's lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies. On July 16th, the company announced that it has entered into an asset transfer agreement with Hydra Biosciences, Inc. for the transfer of all of Hydra's interest in certain intellectual property relating to Hydra's CatSper ion channel target portfolio.
LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).
DARE is a pre-revenue, clinical-stage company engaged in the development of novel therapeutic technologies targeting unmet needs in women’s health. In July 2017, DARE obtained worldwide rights (licensed from ADVA-Tec) to Ovaprene, the company’s lead development program. While certain features of vaginal rings (including effectiveness, reversibility and convenience of monthly use) score high in consumer surveys and studies, hormone-related side-effects (including risk of serious cardiovascular events) are an oft-cited drawback of currently available options, such as NuvaRing (etonogestrel/ethinyl estradiol).